Dr Reddys unveils Gemcitabine for Injection in US

28 Jul 2011 Evaluate

Dr Reddy’s Laboratories has launched Gemcitabine for Injection (200 mg/vial and 1 g/vial), a bioequivalent generic version of Gemzar in the US market, following the approval by the United States Food & Drug Administration (USFDA) of Dr Reddy’s Abbreviated New Drug Application (ANDA) for Gemcitabine for injection.

The Gemzar brand had US sales of about $634 million for the most recent twelve months ending May 31, 2011. The company’s Gemcitabine for Injection 200mg/vial and 1 g/vial strengths are available in single-use vials.

Dr Reddys, a global pharmaceutical company, has a global presence in more than 100 countries, with subsidiaries in the US, UK, Russia, Germany and Brazil; joint ventures in China, South Africa and Australia; representative offices in 16 countries and third-party distribution set ups in 21 countries.

Dr. Reddys Lab Share Price

6080.25 -14.85 (-0.24%)
14-Jun-2024 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1515.00
Dr. Reddys Lab 6080.25
Cipla 1565.50
Zydus Lifesciences 1110.95
Lupin 1601.00
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.